Mission
Guiding Principles
FOCUSED ON ADVANCING GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC RARE DISEASES
Solid Biosciences is a life sciences company focused on advancing a portfolio of gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases.
see "attributes' tool for settings for this row
Guiding Principles
Solid is purpose-built to identify and develop the most promising approaches to address these diseases at all stages.
FOCUSED
We are focused on developing transformative treatments to improve the lives of patients with neuromuscular and cardiac diseases
PATIENT CENTRIC
We start with patients and their unmet needs.
COLLABORATIVE
We are working collectively with all stakeholders — industry, academia, government, and community — to advance our gene therapy candidates to better understand their potential to benefit patients.
CENTER OF EXCELLENCE
We are a catalyst bringing together the best knowledge to address all aspects of these diseases.